Delivery Order SPE2DB25D3110-SPE2DB25FTEEV
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Myrbetriq ER 50 mg tablets (90-count) with a ceiling value of $3,977.47. This contract represents a firm fixed-price delivery order under a competitive, non-set-aside procurement and is scheduled for completion by July 25, 2025. The order will be fulfilled from the vendor's Conshohocken, Pennsylvania location, where AmerisourceBergen maintains its corporate office and serves...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Myrbetriq ER 25 mg tablets (90-count units) with a ceiling value of $33,370.13. This firm fixed-price delivery order, which is not set-aside and competitively awarded, is performed at the contractor's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 19, 2025. The contract represents a continuation of AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Myrbetriq ER 50 mg tablets (90-count) with a ceiling value of $16,088.68. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded to the prime contractor. The order is scheduled for completion by September 9, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 4, 2025, for the supply of Myrbetriq ER 50 mg tablets (90-count units) with a ceiling value of $7,796.69. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is scheduled for completion by November 5, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 16, 2025, for the supply of Myrbetriq ER 50 mg tablets (90-count) with a ceiling value of $10,190.42. This is a firm fixed-price delivery order with no set-aside designation, issued as a competitive award to support federal medical procurement needs. The order is set for ultimate completion by July 17, 2025, and will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Myrbetriq ER 50 mg tablets (90-count) with a ceiling value of $6,266.64. This non-set-aside, competitively awarded contract represents a firm fixed price delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The ultimate completion date is set for...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Myrbetriq ER 50 mg tablets (90-count units) valued at $4,037.23. This is a firm fixed price delivery order with no set-aside designation, competitively awarded to the prime contractor. The contract is scheduled for completion by August 28, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Myrbetriq ER 50 mg tablets (90-count) with a ceiling value of $30,440.85. This firm fixed-price delivery order, which is a child contract under a larger vehicle, reflects no set-aside designation and represents a competitively awarded transaction. The order will be fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania, with an...
- The Defense Logistics Agency awarded a $3,853.29 delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for Myrbetriq ER 50 mg tablets (90-count supply). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of August 12, 2025. The contract is performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania, and represents a child delivery order under a larger contract vehicle. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $6,999.35 to AmerisourceBergen Drug Corp for Myrbetriq ER 50 mg tablets (90-count supply) on August 27, 2025, with completion scheduled for August 28, 2025. This firm fixed price, non-set-aside contract was competitively awarded and is being performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The contract represents a routine pharmaceutical delivery supporting federal medical supply requirements....
- SPE2DB25D3110Indefinite Delivery Contract
- SPE2DB25D3110-SPE2DB25FTEEVDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Myrbetriq ER 50 mg tablets (30-count units) with a ceiling value of $3,437.07. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement and is set for ultimate completion by August 27, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 pharmaceutical prime vendor agreement extending through December 2026. The IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a wide range of medications, vaccines, and medical supplies to support military healthcare programs worldwide, including the Defense Health Agency and U.S. Coast Guard. Myrbetriq, a urological medication, reflects the diverse therapeutic portfolio delivered under this strategic contract arrangement.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.4k | 8/26/25 |